Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-848d4c4894-2pzkn Total loading time: 0 Render date: 2024-04-30T22:53:07.193Z Has data issue: false hasContentIssue false

Chapter 4 - Drug utilization, adherence, and unique side effects of targeted therapy in older adults

from Part 1 - Key principles in geriatric oncology

Published online by Cambridge University Press:  05 August 2011

By
Tiffany A. Traina  and
Stuart M. Lichtman
Edited by
Arti Hurria  and
Harvey Jay Cohen
Arti Hurria
Affiliation:
City of Hope Cancer Center, California
Harvey Jay Cohen
Affiliation:
Duke University Medical Center, Durham
Get access

Summary

A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
Practical Geriatric Oncology , pp. 41 - 51
Publisher: Cambridge University Press
Print publication year: 2010

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Yancik, R, Ries, . Aging and cancer in America: demographic and epidemiologic perspectives. Hematol Oncol Clin North Am. 2000;14:17–23.CrossRefGoogle ScholarPubMed
Hutchins, LF, Unger, JM, Crowley, JJ. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med. 1999;341:2061–2067.CrossRefGoogle ScholarPubMed
Talarico, L, Chen, G, Pazdur, R. Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration. J Clin Oncol. 2004;22:4626–4631.CrossRefGoogle ScholarPubMed
Yuen, GJ.Altered pharmacokinetics in the elderly. Clin Geriatr Med. 1990;6:257–267.Google ScholarPubMed
Baker, SD, Grochow, LB. Pharmacology of cancer chemotherapy in the older person. Clin Geriatr Med. 1997;13:169–183.Google ScholarPubMed
Sotaniemi, EA, Arranto, AJ, Pelkonen, O. Age and cytochrome P450-linked drug metabolism in humans: an analysis of 226 subjects with equal histopathologic conditions. Clin Pharmacol Ther. 1997;61:331–339.CrossRefGoogle ScholarPubMed
Sawhney, R, Sehl, M, Naeim, A. Physiologic aspects of aging: impact on cancer management and decision making, part I. Cancer J. 2005;11:449–460.CrossRefGoogle ScholarPubMed
Shah, RR.Drug development and use in the elderly: search for the right dose and dosing regimen (parts I and II). Br J Clin Pharmacol. 2004;58:452–469.CrossRefGoogle Scholar
Vestal, RE.Aging and pharmacology. Cancer. 1997;80:1302–1310.3.0.CO;2-B>CrossRefGoogle ScholarPubMed
Fehrman-Ekholm, I, Skeppholm, L. Renal function in the elderly (>70 years old) measured by means of iohexol clearance, serum creatinine, serum urea and estimated clearance. Scand J Urol Nephrol. 2004;38:73–77.CrossRefGoogle ScholarPubMed
Lindeman, RD, Tobin, J, Shock, NW. Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc. 1985;33:278–285.CrossRefGoogle ScholarPubMed
Burkhardt, H, Bojarsky, G, Gretz, N, Gladisch, R. Creatinine clearance, Cockcroft-Gault formula and cystatin C: estimators of true glomerular filtration rate in the elderly?Gerontology. 2002;48:140–146.CrossRefGoogle ScholarPubMed
Rimon, E, Kagansky, N, Cojocaru, L. Can creatinine clearance be accurately predicted by formulae in octogenarian in-patients?Q J Med. 2004;97:281–287.CrossRefGoogle ScholarPubMed
Marx, GM, Blake, GM, Galani, E. Evaluation of the Cockroft-Gault, Jelliffe and Wright formulae in estimating renal function in elderly cancer patients. Ann Oncol. 2004;15:291–295.CrossRefGoogle ScholarPubMed
Levey, AS, Bosch, JP, Lewis, JB. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130: 461–470.CrossRefGoogle ScholarPubMed
Lichtman, SM, Wildiers, H, Launay-Vacher, V. International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency. Eur J Cancer. 2007;43:14–34.CrossRefGoogle ScholarPubMed
Hurria, A, Lichtman, SM. Clinical pharmacology of cancer therapies in older adults. Br J Cancer. 2008;98:517–522.CrossRefGoogle ScholarPubMed
Lichtman, SM.Older patients and the shifting focus of cancer care. Oncology. 2009;23:86, 88.Google ScholarPubMed
Lichtman, SM, Wildiers, H, Chatelut, E. International Society of Geriatric Oncology Chemotherapy Taskforce: evaluation of chemotherapy in older patients – an analysis of the medical literature. J Clin Oncol. 2007;25:1832–1843.CrossRefGoogle ScholarPubMed
Lichtman, SM.Therapy insight: therapeutic challenges in the treatment of elderly cancer patients. Natl Clin Pract Oncol. 2006;3:86–93.CrossRefGoogle ScholarPubMed
Fulton, MM, Allen, ER. Polypharmacy in the elderly: a literature review. J Am Acad Nurse Pract. 2005;17:123–132.CrossRefGoogle ScholarPubMed
Lichtman, SM, Boparai, MK. Anticancer drug therapy in the older cancer patient: pharmacology and polypharmacy. Curr Treat Options Oncol. 2008;9:191–203.CrossRefGoogle ScholarPubMed
Bergman-Evans, B.AIDES to improving medication adherence in older adults. Geriatr Nurs. 2006;27:174–182; quiz 83.CrossRefGoogle ScholarPubMed
Partridge, AH, Avorn, J, Wang, PS. Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst. 2002;94:652–661.CrossRefGoogle ScholarPubMed
Tsang, J, Rudychev, I, Pescatore, SL. Prescription compliance and persistency in chronic myelogenous leukemia (CML) and gastrointestinal stromal tumor (GIST) patients (pts) on imatinib (IM). J Clin Oncol Meet Abstr. 2006;24:6119.Google Scholar
Partridge, AH, LaFountain, A, Mayer, E. Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol. 2008;26:556–562.CrossRefGoogle ScholarPubMed
Osterberg, L, Blaschke, T. Adherence to medication. N Engl J Med. 2005;353:487–497.CrossRefGoogle ScholarPubMed
Hartigan, K.Patient education: the cornerstone of successful oral chemotherapy treatment. Clin J Oncol Nurs. 2003;7:21–24.CrossRefGoogle ScholarPubMed
Fick, DM, Cooper, JW, Wade, WE. Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med. 2003;163:2716–2724.CrossRefGoogle Scholar
Beers, MH.Explicit criteria for determining potentially inappropriate medication use by the elderly: an update. Arch Intern Med. 1997;157:1531–1536.CrossRefGoogle ScholarPubMed
Barry, PJ, O';Keefe, N, O';Connor, KA. Inappropriate prescribing in the elderly: a comparison of the Beers criteria and the improved prescribing in the elderly tool (IPET) in acutely ill elderly hospitalized patients. J Clin Pharm Ther. 2006;31:617–626.CrossRefGoogle ScholarPubMed
Cannon, KT, Choi, MM, Zuniga, MA. Potentially inappropriate medication use in elderly patients receiving home health care: a retrospective data analysis. Am J Geriatr Pharmacother. 2006;4:134–143.CrossRefGoogle ScholarPubMed
Budnitz, DS, Shehab, N, Kegler, SR. Medication use leading to emergency department visits for adverse drug events in older adults. Ann Intern Med. 2007;147:755–765.CrossRefGoogle ScholarPubMed
Love, RR, Philips, J. Oophorectomy for breast cancer: history revisited. J Natl Cancer Inst. 2002;94:1433–1434.CrossRefGoogle ScholarPubMed
,Early Breast Cancer Trialists'; Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and a 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687–1717.CrossRefGoogle Scholar
Osborne, CK. Tamoxifen in the treatment of breast cancer. N Engl J Med. 1998;339:1609–1618.CrossRefGoogle ScholarPubMed
Braithwaite, RS, Chlebowski, RT, Lau, J. Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med. 2003;18:937–947.CrossRefGoogle ScholarPubMed
Baum, M, Budzar, AU, Cuzick, J. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet. 2002;359:2131–2139.Google ScholarPubMed
Goss, PE, Ingle, JN, Martino, S. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst. 2005;97:1262–1271.CrossRefGoogle ScholarPubMed
Coombes, RC, Hall, E, Gibson, LJ. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004;350:1081–1092.CrossRefGoogle ScholarPubMed
Thurlimann, BJ, Keshaviah, A, Mouridsen, H. BIG 1–98: randomized double-blind phase III study to evaluate letrozole (L) vs. tamoxifen (T) as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. Proc Am Soc Clin Oncol. 2005;23(suppl 16):511.CrossRefGoogle Scholar
Muss, HB, Tu, D, Ingle, JN. Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17. J Clin Oncol. 2008;26:1956–1964.CrossRefGoogle ScholarPubMed
Cuppone, F, Bria, E, Verma, S. Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer? Meta-analysis of randomized trials. Cancer. 2008;112:260–267.CrossRefGoogle ScholarPubMed
Saltz, L, Clarke, S, Díaz-Rubio, E. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26:2013–2019.CrossRefGoogle ScholarPubMed
Hurwitz, H, Fehrenbacher, L, Novotny, W. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–2342.CrossRefGoogle ScholarPubMed
Kabbinavar, FF, Schulz, J, McCleod, M. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol. 2005;23:3697–3705.CrossRefGoogle ScholarPubMed
Scappaticci, FA, Skillings, JR, Holden, SN. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst. 2007;99:1232–1239.CrossRefGoogle ScholarPubMed
Kozloff, MF, Sugrue, MM, Purdie, DM. Safety and effectiveness of bevacizumab (BV) and chemotherapy (CT) in elderly patients (pts) with metastatic colorectal cancer (mCRC): results from the BRiTE observational cohort study. Proc Am Soc Clin Oncol. 2008;26:4026.CrossRefGoogle Scholar
Ramalingam, SS, Dahlberg, SE, Langer, CJ. Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol. 2008;26:60–65.CrossRefGoogle ScholarPubMed
,FDA approval for bevacizumab. National Cancer Institute Web site. Available at: http://www.cancer.gov/cancertopics/druginfo/fda-bevacizumab.
Richardson, S, Dickler, M, Dang, C. Tolerance of bevacizumab in an older patient population: The Memorial Sloan-Kettering Cancer Center (MSKCC) experience. Proc Am Soc Clin Oncol.2008;26(suppl 15):9569.CrossRefGoogle Scholar
Slamon, DJ, Leyland-Jones, B, Shak, S. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783–792.CrossRefGoogle Scholar
Fyfe, GA, Mass, R, Murphy, M. Survival benefit of traztuzumab (Herceptin) and chemotherapy in older (age > 60) patients. Proc Am Soc Clin Oncol. 2001;20:189.Google Scholar
Piccart-Gebhart, MJ, Procter, M, Leyland-Jones, B. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353:1659–1672.CrossRefGoogle ScholarPubMed
Gupta‌, A, Mekan, S, Eckman, M.Trastuzumab for all? A decision analysis examining tradeoffs between efficacy and cardiac toxicity of adjuvant therapy in HER2-positive breast cancer. Proc Am Soc Clin Oncol. 2006;24(suppl 18): 6022.Google Scholar
Cunningham, D, Humblet, Y, Siena, S. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351:337–345.CrossRefGoogle ScholarPubMed
Lenz, HJ, Cutsem, E, Khambata-Ford, S. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol. 2006;24:4914–4921.CrossRefGoogle ScholarPubMed
Gebbia, V, Del Prete, S, Borsellino, N. Efficacy and safety of cetuximab/irinotecan in chemotherapy-refractory metastatic colorectal adenocarcinomas: a clinical practice setting, multicenter experience. Clin Colorectal Cancer. 2006;5:422–428.CrossRefGoogle ScholarPubMed
Vincenzi, B, Santini, D, Rabitti, C. Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: a single centre phase II trial. Br J Cancer. 2006;94:792–797.CrossRefGoogle ScholarPubMed
Bouchahda, M, Macarulla, T, Spano, JP. Cetuximab efficacy and safety in a retrospective cohort of elderly patients with heavily pretreated metastatic colorectal cancer. Crit Rev Oncol Hematol. 2008;67:255–262.CrossRefGoogle Scholar
Rocha-Lima, CM, Soares, HP, Raez, . EGFR targeting of solid tumors. Cancer Control. 2007;14:295–304.CrossRefGoogle ScholarPubMed
Cutsem, E, Peeters, M, Siena, S. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol. 2007;25:1658–1664.CrossRefGoogle ScholarPubMed
Bonner, JA, Harari, PM, Giralt, J. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354:567–578.CrossRefGoogle ScholarPubMed
Coiffier, B, Haioun, C, Ketterer, N. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood. 1998;92:1927–1932.Google ScholarPubMed
Coiffier, B, Lepage, E, Briere, J. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235–242.CrossRefGoogle ScholarPubMed
Habermann, TM, Weller, EA, Morrison, VA. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006;24:3121–3127.CrossRefGoogle ScholarPubMed
Cortes, J, Kantarjian, H. New targeted approaches in chronic myeloid leukemia. J Clin Oncol. 2005;23:6316–6324.CrossRefGoogle ScholarPubMed
Peng, B, Hayes, M, Resta, D. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol. 2004;22:935–942.CrossRefGoogle Scholar
Brandwein, JM, Gupta, V, Wells, RA. Treatment of elderly patients with acute lymphoblastic leukemia – evidence for a benefit of imatinib in BCR-ABL positive patients. Leuk Res. 2005;29:1381–1386.CrossRefGoogle ScholarPubMed
Latagliata, R, Breccia, M, Carmosino, I. Elderly patients with Ph+ chronic myelogenous leukemia (CML): results of imatinib mesylate treatment. Leuk Res. 2005;29:287–291.CrossRefGoogle Scholar
Blay, JY, Cesne, A, Ray-Coquard, I. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. J Clin Oncol. 2007;25:1107–1113.CrossRefGoogle ScholarPubMed
Shepherd, FA, Rodrigues Pereira, J, Ciuleanu, T. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353:123– 132.CrossRefGoogle ScholarPubMed
Wheatley-Price, P, Ding, K, Seymour, L. Erlotinib for advanced non-small-cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol. 2008;26:2350–2357.CrossRefGoogle ScholarPubMed
Jackman, DM, Yeap, BY, Lindeman, NI. Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J Clin Oncol. 2007;25:760–766.CrossRefGoogle ScholarPubMed
Miller, AA, Murry, DJ, Owzar, K. Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101. J Clin Oncol. 2007;25:3055–3060.CrossRefGoogle ScholarPubMed
Ratain, MJ, Eisen, T, Stadler, WM. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006;24: 2505–2512.CrossRefGoogle ScholarPubMed
Llovet, JM, Ricci, S, Mazzaferro, V. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–390.CrossRefGoogle ScholarPubMed
Miller, AA, Murry, DJ, Owzar, K. Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. J Clin Oncol. 2009;27:1800–1805.CrossRefGoogle ScholarPubMed
Rini, BI, Michaelson, MD, Rosenberg, JE. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol. 2008;26:3743–3748.CrossRefGoogle ScholarPubMed
Motzer, RJ, Hutson, TE, Tomczak, P. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115–124.CrossRefGoogle ScholarPubMed
Joensuu, H.Sunitinib for imatinib-resistant GIST. Lancet. 2006;368:1303–1304.CrossRefGoogle ScholarPubMed
Schmidinger, M, Zielinski, CC, Vogl, UM. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2008;26:5204–5212.CrossRefGoogle ScholarPubMed
Geyer, CE, Forster, J, Lindquist, D. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355:2733–2743.CrossRefGoogle ScholarPubMed
Perez, EA.Cardiac toxicity of ErbB2-targeted therapies: what do we know?Clin Breast Cancer. 2008;8(suppl 3):114–120.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×